The combination of tislelizumab and anlotinib demonstrated promising antitumor activity with a manageable safety profile as first-line therapy in patients with advanced PSC.
The efficacy and safety of tislelizumab plus anlotinib as first-line treatment in advanced pulmonary sarcomatoid carcinoma: a single-arm phase II trial
Zhimin Zeng·Anwen Liu·Xiaoqiang Zhang·Wenqian Huang·Le Xiong·Jing Cai·Ziye Chen·Chenyi Liu·Fujuan Zeng·Yue’e Zheng·Li Huang